🩺 Brief summary
A new study has revealed an association between Wegovy, a drug used to treat obesity, and increased risks of a rare condition known as ischemic optic neuropathy (ION), which may lead to sudden loss of vision. The study showed that the likelihood of developing this condition is five times higher with Wegovy compared with other drugs containing semaglutide such as Ozempic. These findings highlight the importance of continuous drug safety monitoring, especially with the growing spread of GLP-1 drugs and their use in multiple fields.
🦠 Introduction to Wegovy and ION
Wegovy is widely used to treat obesity, and it is one of the drugs in the GLP-1 class that works to modify body processes related to appetite and blood sugar levels. With the increasing use of this drug, questions have begun to arise about its long-term safety, especially regarding its effects on the eye.
The condition ischemic optic neuropathy (ION) means reduced blood flow to the optic nerve, which threatens to disrupt the visual signals that reach the brain, sometimes causing a sudden loss of the ability to see in one eye or both eyes.
🧬 The detailed role of the FDA study on existing drugs
To uncover the potential relationship between Wegovy and ION, researchers analyzed reports from the U.S. Food and Drug Administration adverse event reporting system (FDA) from December 2017 to December 2024. The research team used the FAERS database, which includes more than 30.6 million reports of unwanted side effects associated with various drugs.
In the details of reports related to semaglutide drugs, 31,774 reporting cases were recorded, and the average patient age was 56 years, of whom 54% were women. The study included a comparison between multiple drugs such as Ozempic (for type 2 diabetes), Wegovy (for obesity), and Rybelsus (oral tablet), in addition to drugs such as Mounjaro and Zepbound that contain similar compounds.
🧠 Wegovy shows a stronger association with ION risks
Although the number of ION reports associated with Ozempic was higher (47 reports compared with 28 for Wegovy), the “statistical signal,” which reflects the strength of the relationship, was highest with Wegovy, where the likelihood of infection was recorded as 75 times higher than expected, compared with about 19 times for Ozempic, and 21 for the generic forms of semaglutide.
No ION cases were recorded with Rybelsus, the oral form of the drug, suggesting that the potential effects may differ depending on the method of administration and the dose.
The study also revealed striking differences between the sexes, as the data showed that men taking Wegovy suffer from higher risks, with the odds estimated at an 116-fold increase, while the highest risks among women were with Ozempic. Overall, the risk among men was three times higher than among women.
🌱 Possible mechanisms behind these elevated risks
The researchers assume that the higher dose of Wegovy compared with Ozempic, along with the drug’s rapid effect when injected, may contribute to reduced blood flow to the optic nerve. This may occur through several mechanisms, including:
- A sudden drop in blood pressure, which affects blood flow to the retina and optic nerve.
- Fluid loss and instability in the autonomic nervous system (autonomic nervous system).
On the other hand, the absence of ION reports with Rybelsus was explained by its limited absorption and slower effect, since it is taken orally in lower doses.
However, this study did not prove a direct cause of the condition, but rather revealed statistical links that call for further research.
🩺 The need for more studies and follow-up
The FDA reporting system is an important tool for monitoring side effects, but it suffers from several limitations, such as the inability to determine the exact incidence rate of the condition, as well as a lack of medical details about patients.
There is still a need for in-depth studies that follow patients systematically, in order to determine definitively the extent of the relationship between dose and drug type and the risk of ION.
The researchers emphasized the importance of these findings as they are the first to propose a link based on drug composition and dose, while calling for proactive assessment to guide medical policies and establish safer rules for prescribing drugs.
🧪 Opinions of eye experts and the medical community
Eye specialists discussed the study findings, stressing the need to monitor patients using anti-obesity drugs from the GLP-1 class, and the need to conduct other research clarifying the danger, especially with the increasing reporting of visual problems with these drugs.
🌍 The spread of GLP-1 drug use and public health challenges
Figures indicate rising obesity rates globally, especially in the United Kingdom, where 29% of the population is obese, and people with overweight or obesity make up a community of 64%.
The popularity of GLP-1 drugs used to treat type 2 diabetes has increased, extending their use to weight loss, reducing the risks of cardiovascular disease, stroke, and even reducing the likelihood of dementia.
With the expected increase in prescriptions for these drugs, debate has arisen about how safe it is to use them, especially in children over the age of twelve, given the potential for a future increase in rare side effects such as ION.
🌿 Benefits versus risks
Although this class of drugs shows promising abilities in improving eye conditions such as age-related macular degeneration (age-related macular degeneration) and eye inflammations such as uveitis, researchers call for balance in measures between the medical benefits and the rare serious risks they may cause.
In conclusion, monitoring drug developments and research, and gaining a deep understanding of the effects of all GLP-1 drugs, remain essential to preserve patient safety while continuing to benefit from the many advantages of these modern drugs.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
